• Women's Health Nursing
• /
• v.24 no.1
• /
• pp.71-79
• /
• 2018

Purpose: The purpose of this study was to identify effects of attitude, subjective norm, and perceived behavior control toward Human Papillomavirus (HPV) on HPV vaccination intention in female high school students. Methods: Subjects of this study were female students aged 16 to 17 years, the optimal age group of HPV vaccination, arbitrarily selected from three high schools in B city. A total of 140 students agreed to participate in this study. Data were analyzed using descriptive statistics, t-test, ANOVA, correlation, and stepwise multiple regression. Results: Attitude, subjective norm, and perceived behavior control toward HPV were factors influencing HPV vaccination intention of subjects. Perceived behavior control toward HPV vaccination was the most influential factor. These factors accounted for 49% of HPV vaccination intention. Conclusion: These results suggest a need to increase perceived behavior control to increase HPV vaccination intention. The government needs to establish a national policy system such as financial support for HPV vaccines and free vaccinations so that students are aware that HPV vaccines can be easily inoculated.

• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.4
• /
• pp.1521-1525
• /
• 2014

Background: Human papillomavirus (HPV) is one of the most common sexually transmitted infections worldwide and the association between HPV infection and genital cancers has been well established. This study concerned the possible role of HPV infection in colorectal carcinoma (CRC) in the Iranian population. Materials and Methods: We examined 80 tissues obtained from patients with colorectal cancer consisting of 58 colon cancer samples and 22 rectal cancer samples and 80 tissues from patients with unremarkable pathologic changes as matched controls by sex, study center and anatomical sites. HPV infection and genotypes were detected using nested PCR and sequencing methods, respectively. Results: HPV DNA was detected in 5/80 (6.25%) cases including 1 of 22 (4.54%) patients with rectum cancer and 4 of 58 (6.9%) patients with colon cancer and 1/80 (1.25%) of controls. Furthermore, HPV-18 was detected as the most frequent type and we found no significant correlation between prevalence of HPV infection and anatomical sub- sites. Conclusions: Although a causal relation between human papillomavirus and colorectal cancer was not found through this study, analysis of medical records pointed to a possible role for high- risk types of HPV in increasing the potential of aggressiveness in colorectal cancer. This study shows a particular frequency of HPV genotypes in patients with colorectal cancer in Iran. Since HPV vaccines are limited to a few types of virus, using cohort studies in different geographical zones to screen for patterns of HPV infection in different organs might increase the efficacy and optimization of the current vaccines.

• Proceedings of the PSK Conference
• /
• 2004.10a
• /
• pp.104-104
• /
• 2004

• Journal of Microbiology and Biotechnology
• /
• v.25 no.6
• /
• pp.936-940
• /
• 2015

Human papillomavirus (HPV) type 52 is a high-risk HPV responsible for cervical cancer. HPV type 52 is common around the world and is the most common in some Asian regions. The available prophylactic HPV vaccines protect only from HPV types 16 and 18. Supplementing economical vaccines that target HPV type 52 may satisfactorily complement available prophylactic vaccines. A codon-adapted HPV 52 L1 gene was expressed in the methylotrophic yeast Hansenula polymorpha, which is used as an industrial platform for economical hepatitis B surface antigen particle production in China. We found that the recombinant proteins produced in this expression system could form virus-like particles (VLPs) with diameters of approximately 50 nm. This study suggests that the HPV 52 VLPs produced in this platform may satisfactorily complement available prophylactic vaccines in fighting against HPVs prevalent in Asia.

• Asian Pacific Journal of Cancer Prevention
• /
• v.14 no.7
• /
• pp.4015-4023
• /
• 2013

Cancer of the cervix is the third most common cancer in women worldwide, more than 85% of the cases occurring in developing countries such as China. In China, since a national cancer registry is already set up but with geographically limited data generated, the burden of cervical cancer is believed to be underestimated. High-risk human papillomavirus (HR-HPV) prevalence among women attending routine cervical cancer screening programs has been shown to correlate well with cervical cancer incidence rates based on independently obtained HPV prevalence data as well as findings for the worldwide cervical cancer burden. Therefore, reviewing data on HR-HPV prevalence in population-based screening studies and hospital-based case studies will be important in the context of better understanding the cervical cancer burden and for the evaluation of the potential impact of HPV vaccination in the country. With the advent of prophylactic vaccines, significant progress is likely to be made in cervical cancer prevention. This article reviews available data on the HPV epidemiology over a 12-year time period (2001-2012) in mainland China under different epidemiological aspects: by age group of study population, by ethnicity, by geographic area, as well as time period. The authors also review the potential acceptability of HPV vaccination among Chinese women.

• Korean journal of aerospace and environmental medicine
• /
• v.31 no.1
• /
• pp.21-23
• /
• 2021

Purpose: Human papillomavirus (HPV) vaccination schedule is recommended by Strategic Advisory Group of Experts on Immunization of World Health Organization to achieve high efficacy and immunogenicity. However, the patients often cannot keep up their schedule for several reasons. Methods: Monthly numbers of visitors for HPV vaccination between 2019 and 2021 were analyzed to measure the impact of coronavirus disease-19 (COVID-19) outbreak which was the main cause of this delay. Results: In February 2020, the number of foreign patients vaccinated with HPV was dropped suddenly due to COVID-19. Prior to this impact, the average patients per month for HPV vaccination was 160 (95% confidence interval [CI]: 143-176). It was then 30 (95% CI: 20-40). However recent trends show a gradual recovery. Conclusion: If a woman is pregnant after starting the HPV vaccine series, the reminder doses should be delayed until she is no longer pregnant. If this series is interrupted for any length of time, it can be resumed without restarting the series. HPV vaccine series need to be administered with a minimum interval of 14 days before or after administration of COVID-19 vaccines.

• The Journal of Korean Academic Society of Nursing Education
• /
• v.23 no.4
• /
• pp.367-377
• /
• 2017

Purpose: This descriptive research study aims to investigate influential factors on human papillomavirus vaccines, among parents who have elementary school daughters. Methods: This study was conducted with 210 parents whose children are elementary school girls, aged 9 to 12 years, in G Metropolitan City. Data were collected from August 17 to September 12, 2015 using structured questionnaires. A descriptive statistical analysis, a t-test, a ${\chi}^2-test$, a Fisher's exact test, and a logistic regression using SPSS/WIN 21.0. Results: The influential factors on the human papillomavirus vaccination intention were confirmed to be three variables: cervical cancer knowledge, perceived sensitivity, and perceived barriers. Conclusion: An intervention program, both to increase the sensitivity of vaccination and to decrease barriers, should be developed so as to improve parents' health beliefs towards human papillomavirus vaccination.

• Journal of the Korean neurological association
• /
• v.36 no.4
• /
• pp.318-321
• /
• 2018

We describe a 44-year-old woman with paresthesia, fatigue, and palpitation, 10 days after human papillomavirus (HPV) vaccination. The quantitative sensory test showed abnormal detection threshold in her foot. Tilt test result indicated postural orthostatic tachycardia syndrome. Symptoms were improved after immunomodulating therapy, pain control drug, and oral beta blocker medication. This is first case report for small fiber neuropathy and autonomic dysfunction after HPV vaccination in Korea.

• Journal of Pharmaceutical Investigation
• /
• v.31 no.3
• /
• pp.185-190
• /
• 2001

Human papillomavirus (HPV) infection is known to cause cervical cancers. Human papillomavirus-like particles (VLP) have been studied as preventive vaccines of cervical cancers. To develop VLP as a therapeutic gene carrier, we studied the method to encapsulate cytokine genes in virus-like particles. HPV type 16 capsid L1 genes were amplified by polymerase chain reaction and cloned into T vector. L1 gene was then inserted into baculovirus transfer vector. The clone of baculovirus encoding L1 gene was isolated and used to express L1 protein in Sf 21 insect cells. VLP were purified by CsCl density gradient and ultracentrifugation. VLP were disassembled to capsomer units by treatment of a reducing agent. Given that interleukin-2 (IL-2) genes have been used in anticancer gene therapy and as a molecular adjuvant, IL-2 cytokine plasmids were chosen as a model gene. IL-2 plasmids were incubated with the disassembled capsomer suspension. To reassemble the particles, the mixture of capsomers and cytokine plasmids was dialyzed. The disassembly and reassembly of VLP were confirmed by transmission electron microscopy. The entrapment of cytokine plasmids in reassembled VLP was tested by the stability of plasmids against DNase I. After treatment of reassembled virus-like particles with DNase I, discrete IL-2 DNA band was observed. Our results indicate that IL-2 cytokine plasmid (3.5 kb size) can be encapsulated in the virus-like particles, suggesting the potential of VLP as a gene delivery system. Moreover, VLP containing the adjuvant cytokine plasmids might function as more effective subunit vaccines.

• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.6
• /
• pp.2447-2451
• /
• 2014

Human papillomavirus (HPV) is the primary etiologic agent of cervical cancer. Consideration of safety and non human leukocyte antigen restriction, protein vaccine has become the most likely form of HPV therapeutic vaccine, although none have so far been reported as effective. Since tumor cells consistently express the two proteins E6 and E7, most therapeutic vaccines target one or both of them. In this study, we fabricated DC vaccines by transducing replication-defective recombinant adenoviruses expressing E6/E7 fusion gene of HPV-16, to investigate the lethal effects of specific cytotoxic T lymphocytes (CTL) against CaSki cells in vitro. Mouse immature dendritic cells (DC) were generated from bone marrow, and transfected with pAd-E6/E7 to prepare a DC vaccine and to induce specific CTL. The surface expression of CD40, CD68, MHC II and CD11c was assessed by flow cytometry (FCM), and the lethal effects of CTL against CaSki cells were determined by DAPI, FCM and CCK-8 methods. Immature mouse DC was successfully transfected by pAd-E6/E7 in vitro, and the transfecting efficiency was 40%-50%. A DC vaccine was successfully prepared and was used to induce specific CTL. Experimental results showed that the percentage of apoptosis and killing rate of CaSki cells were significantly increased by coculturing with the specific CTL (p <0.05). These results illustrated that a DC vaccine modified by HPV-16 E6/E7 gene can induce apoptosis of CaSki cells by inducing CTL, which may be used as a new strategy for biological treatment of cervical cancer.